Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Cian McEllistrim, MD, Mary R Cahill, MD, Philip Murphy, PhD BPharm, Vitaliy Mykytiv, MD, John Quinn, Amanda Bray, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Grace Hirakata, Imelda Parker, Andres Hernando, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 3163.

https://doi.org/10.1182/blood.V130.Suppl_1.3163.3163

Published: 2017

Journal Articles

Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP

Serika Naicker, BSc, PhD, Athina Rigalou, BSc MSc, Cian McEllistrim, MB, BCh, BAO, Alessandro Natoni, PhD, Christopher Chiu, Kate Sasser, PhD, Aideen Ryan, BSc,PhD, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 121.

https://doi.org/10.1182/blood.V130.Suppl_1.121.121

Published: 2017

Journal Articles

Mesenchymal Stromal Cell Sialylation Enhances Immune Suppression in Multiple Myeloma

Kevin Lynch, BSc, MSc, O'Malley Grace, BSc, Aideen Ryan, BSc,PhD, Thomas Ritter, BSc, PhD, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 124.

https://doi.org/10.1182/blood.V130.Suppl_1.124.124

Published: 2017

Journal Articles

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Daniel J. DeAngelo, MD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, Anjali S. Advani, MD, Paula Marlton, MBBS, Michael O'Dwyer, MD, John L Magnani, PhD, Helen M. Thackray, MD, Pamela S. Becker, MD PhD

Blood (2017) 130 (Supplement 1): 894.

https://doi.org/10.1182/blood.V130.Suppl_1.894.894

Published: 2017

Journal Articles

Interleukin-6 Drives Multiple Myeloma Progression through Upregulating of CD147/Emmprin Expression and Its Sialylation

Yanmeng Wang, Rong Fan, Li Lei, PhD, Aiying Wang, Xiaman Wang, Shen Ying, Hongli Chen, Caoilfhionn Connolly, MD, Kim De Veirman, Aili He, MD, Karin Vanderkerken, PhD, Michael O'Dwyer, MD, Jinsong Hu, PhD

Blood (2017) 130 (Supplement 1): 3037.

https://doi.org/10.1182/blood.V130.Suppl_1.3037.3037

Published: 2017

Journal Articles

Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma

John Daly, MSc, Tony Duggan, BSc, Jinsong Hu, PhD, Alessandro Natoni, PhD, Subhashis Sarkar, PhD, Lucy Kirkham-McCarthy, MSc, Cian McEllistrim, MD, Janusz Krawczyk, MD, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 1799.

https://doi.org/10.1182/blood.V130.Suppl_1.1799.1799

Published: 2017

Journal Articles

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Steven Coutre, MD, John C. Byrd, MD, Peter Hillmen, Jacqueline C. Barrientos, MD, Paul M. Barr, Stephen Devereux, PhD FRCP, FRCPath, Tadeusz Robak, MD PhD, Thomas J. Kipps, MD, PhD, Anna Schuh, MDPhD, Carol Moreno, MD, Richard R. Furman, Jan Burger, MD PhD, Michael O'Dwyer, MD, Paolo Ghia, Rudolph Valentino, PharmD, Samuel Suzuki, MS, MBA, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, Susan M. O'Brien, MD

Blood (2016) 128 (22): 4383.

https://doi.org/10.1182/blood.V128.22.4383.4383

Published: 2016

Journal Articles

Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2 TM )

Blood (2015) 126 (23): 495.

https://doi.org/10.1182/blood.V126.23.495.495

Published: 2015

Journal Articles

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Su Wai Maung, MBBS, MRCP(UK), Cian McEllistrim, MRCPI, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Margaret Murray, FRCPath, Michael O'Dwyer, MD, Patrick Thornton, FRCPath, Emma Groarke, MRCPI, Denis O'Keeffe, MD MRCPath, Maeve Leahy, MD MRCPath, Aine Burke, MRCP,MD, Peter O'Gorman, Carmel Weldon, M.Sc, MRCPI, Gerard Crotty, MD FRCPath, Meegahage Ratnakanthi Perera, MDMRCPath,MBBS, Cathie Burke, RN, Johnny McHugh, FRCPath, Helen Enright, MD FRCPI, FRCPath, Ronan Desmond, MD FRCPath

Blood (2015) 126 (23): 5258.

https://doi.org/10.1182/blood.V126.23.5258.5258

Published: 2015

Journal Articles

Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma

Niamh Keane, MB BCh MRCPI, Mairead Reidy, PhD, Alessandro Natoni, PhD, Michael O'Dwyer, MD FRCPI, FRCPath

Blood (2015) 126 (23): 3007.

https://doi.org/10.1182/blood.V126.23.3007.3007

Published: 2015

Journal Articles

Estimating the Relative Effectiveness of Treatments in Relapsed/Refractory Multiple Myeloma through a Systematic Review and Network Meta-Analysis

Kai Ruggeri, PhD, Áine Maguire, MSc, Susanne Schmitz, PhD, Elisa Haller, MSc, Cathal Walsh, PhD, Jack Bowden, PhD, Isla Kuhn, Ayesha Khan, PhD, Gordon Cook, MD PhD, Michael O'Dwyer, MD

Blood (2015) 126 (23): 2103.

https://doi.org/10.1182/blood.V126.23.2103.2103

Published: 2015

Journal Articles

E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271

Alessandro Natoni, PhD, Theodore A.G. Smith, PhD, Niamh Keane, MB, MRCP, Silvia C. Locatelli-Hoops, PhD, Isabela Oliva, William E. Fogler, PhD, John L. Magnani, PhD, Michael O'Dwyer, MD

Blood (2015) 126 (23): 1805.

https://doi.org/10.1182/blood.V126.23.1805.1805

Published: 2015

Journal Articles

The Dual PIM/PI3-K Inhibitor Ibl-202 Overcomes Microenvironmental Mediated Resistance in Multiple Myeloma and Prevents PIM1 Induced CXCR4 Upregulation

Mairead Reidy, PhD, Marianne VanDijk, PhD, Michael O'Neill, PhD, Michael O'Dwyer, MD FRCPI, FRCPath

Blood (2015) 126 (23): 5350.

https://doi.org/10.1182/blood.V126.23.5350.5350

Published: 2015

Journal Articles

G2/M Arrest Sensitizes Chronic Myelogenous Leukemia Cells to TRAIL-Induced Apoptosis

David Devlin, Medical, Student, Eva Szegezdi, Post-Doctoral, Researcher, Paavilainen Tanja, Student, Orsolya Orosz, Student, Michael O'Dwyer, MD, FRCPath, Michael Carty, Senior, Lecturer, Afshin Samali, PhD, Séverine Cruet Hennequart, PhD

Blood (2010) 116 (21): 4465.

https://doi.org/10.1182/blood.V116.21.4465.4465

Published: 2010

Journal Articles

Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.

Eibhlin Conneally, MB, MRCPI, FRCPath, PhD, Ronan T Swords, MD, MRCPI, FRCPath, Francis J. Giles, MB, MD, FRCPI, FRCPath, Mary Frances McMullin, MD, Philipp le Coutre, Stephen Langabeer, Marzena Wieczorkowska, Cliona McDowell, Brian Moulton, Karine Egan, Michael O'Dwyer, MD, FRCPath

Blood (2010) 116 (21): 3427.

https://doi.org/10.1182/blood.V116.21.3427.3427

Published: 2010

Journal Articles

The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid Leukaemia

Ruth C Morrell, MBBCh, FRCPath, Eva Szegezdi, PhD, Anna Halpin-McCormick, BSc, Karen Cawley, BSc, Afshin Samali, PhD, Michael O'Dwyer, MD, FRCPath

Blood (2010) 116 (21): 1841.

https://doi.org/10.1182/blood.V116.21.1841.1841

Published: 2010

Journal Articles

Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program

Philipp D. le Coutre, MD, Michael O’Dwyer, MD, FRCPI, FRCPath, Tomasz Szczudlo, MD, Richard C. Woodman, MD, Francis J. Giles, MD

Blood (2008) 112 (11): 4271.

https://doi.org/10.1182/blood.V112.11.4271.4271

Published: 2008

NARROW

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP

Mesenchymal Stromal Cell Sialylation Enhances Immune Suppression in Multiple Myeloma

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Interleukin-6 Drives Multiple Myeloma Progression through Upregulating of CD147/Emmprin Expression and Its Sialylation

Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2 TM )

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma

Estimating the Relative Effectiveness of Treatments in Relapsed/Refractory Multiple Myeloma through a Systematic Review and Network Meta-Analysis

E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271

The Dual PIM/PI3-K Inhibitor Ibl-202 Overcomes Microenvironmental Mediated Resistance in Multiple Myeloma and Prevents PIM1 Induced CXCR4 Upregulation

G2/M Arrest Sensitizes Chronic Myelogenous Leukemia Cells to TRAIL-Induced Apoptosis

Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.

The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid Leukaemia

Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only